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Teaser This study can inform different stakeholders on how to conduct, assess, and use patient
preference studies and on when to include patient preference studies in development plans.
Factors and situations influencing the
value of patient preference studies
along the medical product lifecycle: a
literature review
Eline van Overbeeke1,z, Chiara Whichello2,z,
Rosanne Janssens1, Jorien Veldwijk2, Irina Cleemput3,
Steven Simoens1, Juhaeri Juhaeri4, Bennett Levitan5,
Jürgen Kübler6, Esther de Bekker-Grob2 and Isabelle Huys1
1Clinical Pharmacology and Pharmacotherapy, University of Leuven, Herestraat 49 Box 521, 3000 Leuven,
Belgium
2 Erasmus School of Health Policy & Management (ESHPM) and Erasmus Choice Modelling Centre (ECMC),
Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
3Belgian Health Care Knowledge Centre (KCE), Kruidtuinlaan 55, 1000 Brussels, Belgium
4 Sanofi, 55 Corporate Drive, Bridgewater, NJ 08807, USA
5 Janssen Research & Development, 1125 Trenton-Harbourton Road, P.O. Box 200, Titusville, NJ 08560, USA
6Quantitative Scientific Consulting, Europabadstr. 8, 35041 Marburg, Germany
Industry, regulators, health technology assessment (HTA) bodies, and
payers are exploring the use of patient preferences in their decision-
making processes. In general, experience in conducting and assessing
patient preference studies is limited. Here, we performed a systematic
literature search and review to identify factors and situations influencing
the value of patient preference studies, as well as applications throughout
the medical product lifecyle. Factors and situations identified in 113
publications related to the organization, design, and conduct of studies,
and to communication and use of results. Although current use of patient
preferences is limited, we identified possible applications in discovery,
clinical development, marketing authorization, HTA, and postmarketing
phases.
Introduction
The importance of incorporating patient needs and perspectives into decision making through-
out the lifecycles of drugs and medical devices, for the purpose of this study collectively called the
medical product lifecycle (MPLC), is receiving increasing recognition [1–4]. Recognition of the
value of patients’ perspectives has led to a shift in drug development and assessments, from only
looking at clinical outcomes to taking into account the judgements of patients on how these
outcomes affect their lives. This shift originates from the notion that patients should be at the
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Attribute feature of the product under investigation (e.g.
price) [126]
External validity the degree to which it is warranted to
generalize results to other contexts
Internal validity the extent to which a causal conclusion
based on a study is warranted. Such warrant is constituted by
the extent to which a study minimizes systemic error (or
‘bias’)
Level value of the attribute (e.g., US$10) [126]
Patient preferences (patient preference information)
qualitative or quantitative assessments of the relative
desirability or acceptability to patients of specified
alternatives or choices among outcomes or other attributes
that differ among alternative health interventions [4]
Preference elicitation method quantitative methods
collecting quantifiable data that can be reported through
statistical inferences or analysis
Preference exploration method qualitative methods that
collect descriptive data through participant or phenomenon
observation, examining the subjective experiences and
decisions made by participants
Preference-sensitive situation preference-sensitive
decisions are those in which there are multiple diagnostic or
treatment options, and the decision which option to pursue
depends upon the particular preferences of the decision-
maker [3]center of the MPLC, because they are the ones not only gaining the
benefits, but also being exposed to the risks [5].
One option to better understand the patient perspective is
through exploring and eliciting patient preferences (see Glos-
sary). The US Food and Drug Administration (FDA) refers to patient
preferences by defining patient preference information as
‘qualitative or quantitative assessments of the relative desirability
or acceptability to patients of specified alternatives or choices
among outcomes or other attributes that differ among alterna-
tive health interventions’ [4]. Patient preferences can be obtained
through the use of different exploration (qualitative) and elicita-
tion (quantitative) methods [6]. Preference exploration meth-
ods can be defined as qualitative methods that collect descriptive
data through participant or phenomenon observation, and exam-
ining the subjective experiences and decisions made by partici-
pants. Examples of preference exploration methods include semi-
structured interviews and focus groups. Preference elicitation
methods can be defined as quantitative methods collecting
quantifiable data that can be reported through statistical infer-
ences or analysis. Examples of preference elicitation methods
include discrete choice experiments (DCE), analytical hierarchy
process (AHP), and standard gamble. Although methods can be
classified as exploration or elicitation methods, they can also be
classified as structured-weighting, health-state utility, stated-pref-
erence, or revealed-preference methods, as described in the Medi-
cal Device Innovation Consortium (MDIC) Patient Centered
Benefit-Risk Project report [3,7].
Stakeholders, including the pharmaceutical and medical device
industry, regulatory authorities, HTA bodies, payers, clinicians,
academia, and patient organizations, generally agree that there is
value in using patient preferences to inform assessments andPlease cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
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2 www.drugdiscoverytoday.comdecision making [1,3,4,8–13]. In addition, patients themselves
have expressed interest in decision-making processes [14]. Patient
preferences are found to provide additional information on medi-
cal products, such as insights into the relative importance of
clinical outcomes and safety issues, and to help in transparent
communication regarding the incorporation of patient views in
regulatory decision making [1,3,15,16]. Moreover, they can lead to
more relevant, well-informed, transparent, publically trusted, and
patient-centric decisions [3,13,17,18]. In HTA specifically, patient
preferences are believed to provide a health condition perspective
and to improve the usefulness, appropriateness, and acceptability
of the assessments [2,8,19,20]. Also, consideration of patient pre-
ferences in clinical trial design can lead to a lower burden for
patients participating in the trial, and could result in improved
recruitment, retention, and compliance of patients. Moreover, it
could lead to more real-world clinical outcomes if preferences of
patients are considered during the establishment of treatment
arms [4,21–25].
European and US industry, regulators, HTA bodies, and payers
are currently exploring the use of patient preferences in their
processes and decision making. However, in general, these stake-
holders have limited experience in conducting and assessing these
studies. Moreover, they are generally not familiar with factors
influencing the value of these studies, the situations in which
these studies are most valuable, and possible applications of
patient preferences in their processes and decision making [26–
28].
By performing a systematic literature search and review (see SP.I
in the Supplemental information online) focused on the current
measurement and use of patient preferences in Europe and the US,
here we provide an overview of factors and situations that influ-
ence the value of patient preference studies. We also investigated
applications of patient preferences in assessments and decision
making along the MPLC.
Overview of applications of patient preferences along
the medical product lifecycle
A total of 113 publications were included in the literature review
(see SP.II in the Supplemental information online). Before we
explore the factors and situations that influence the value of
patient preference studies in assessments and decision making
along the MPLC, first we give a short overview of how patient
preferences can be used in MPLC phases. Several publications
described that patient preferences can be used in every phase of
the MPLC, from discovery until post marketing [3,29]. Here, we
describe the applications of patient preferences following the
structure of the MPLC (Fig. 1). An overview of the availability
of guidelines and frameworks on the use of patient preferences
throughout these phases is given in Table 1. Currently, the Inno-
vative Medicines Initiative (IMI) Patient Preferences in Benefit–
Risk Assessments during the Drug Life Cycle (PREFER) project is
working on providing recommendations on how patient prefer-
ences can inform decision making throughout the MPLC [9].
Discovery
Patient preferences are used in the discovery of new medical
products [30,31]. They can inform ideation and prototyping.
During ideation, the elicitation of patient preferences can help value of patient preference studies along the medical product lifecycle: a literature review,
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FIGURE 1
Applications of patient preferences along the medical product lifecycle (MPLC). Applications of patient preferences were mapped along the phases of the MPLC.
Applications were identified for all phases of the MPLC. Stages of the MPLC and their organization were identified as they emerged from the literature.
Abbreviations: HTA, Health Technology Assessment; PRO, patient-relevant outcomes; QALY, quality-adjusted life year.
TABLE 1
Availability of guidance on the use of patient preferences along the MPLCa
Phase of MPLC Availability of guidance Refs
Discovery Lack of guidance reported [98]
Preclinical development No guidance identified
Clinical development No guidance identified
Marketing authorization Patient Preference Information – Voluntary Submission, Review in Premarket Approval Applications, Humanitarian
Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling:
Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. US Department of Health and
Human Services, FDA, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research
[4]
MDIC Patient-Centered Benefit–Risk Project Report: A Framework for Incorporating Information on Patient Preferences
regarding Benefit and Risk into Regulatory Assessments of New Medical Technology
[3]
ICH Harmonized Guideline: Revision of M4E Guideline on Enhancing the Format and Structure of Benefit-Risk
Information in ICH
[127]
HTA and reimbursement Kleme et al.: Patient perspective in health technology assessment of pharmaceuticals in Finland [107]
Kievit et al.: Taking patient heterogeneity and preferences into account in health technology assessments [20]
Lack of guidance reported [10,128]
Post marketing No guidance identified
a Abbreviations: ICH, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use.
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care needs. For instance, this is demonstrated by the patient
preference study on fragile X syndrome (FXS) by Cross et al.
[32], described in the report of Selig [3,4,30]. Selig described
how stakeholders sought to get a better understanding of unmet
needs in FXS. Caregiver preferences were quantified for six treat-
ment outcomes. Caregivers found the ability of patients to control
their psychological, gestural, and verbal behavior to be the most
important treatment outcome. Cross et al. [32] stated that these
results would have the potential to inform future drug develop-
ment in FXS [30]. In addition to identifying unmet medical needs,
they can lead to a better understanding of the disease, personalPlease cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.09.015experiences of patients with the disease, and the acceptability of
benefits and risks [3,4,30,33]. Patient preferences can even be used
to inform the design of the target product profile, ensuring that
patient needs are met [34]. During prototyping, patient prefer-
ences can inform adaption of the design of the medical product
[3,4,11].
Preclinical development
Almost no evidence was found on applications of patient prefer-
ences in preclinical development. Patient preference were sug-
gested to ensure that the patient needs are addressed by the
medical product in design validation during preclinical testing value of patient preference studies along the medical product lifecycle: a literature review,
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TABLE 2
Main US and European HTA bodies and payers interested in
patient preferencesa
Country Organization
Belgium Belgian Health Care Knowledge Centre (KCE)
England National Institute for Health and Care Excellence (NICE)
Finland Finnish Medicines Agency (Fimea)
France High Authority of Health (HAS)
Germany Institute for Quality and Efficiency in Health Care (IQWiG)
Scotland Scottish Medicines Consortium (SMC)
The Netherlands Care Institute Netherlands (CVZ)
USA Centers for Medicare & Medicaid Services (CMS)
a Based on Refs [19,29,61,62,65,66,78,81,129].
Review
s
FO
U
N
D
A
TIO
N
R
EV
IEW[3]. No literature was retrieved demonstrating the actual use of
patient preferences during preclinical development.
Clinical development
Patient preferences can be elicited during clinical development to
inform clinical trial design, product design validation, and benefit-
–risk assessment [3]. Patient preferences are currently taken into
account in clinical trial design [3,4,11,30], during which patient
preferences can be used to identify patient-relevant outcomes that
can inform the selection of clinical endpoints [4,22,35–37]. Also,
patient preferences can inform the development of reasonable
inclusion and exclusion criteria. Moreover, they can be used to
define experimental or control treatment arms in doubly random-
ized preference trial (DRPT) designs. In DRPT designs, the effect of
preferences on clinical outcomes can be analyzed [24,25,38–44].
Patient preferences can also be used in clinical trial designs to
calculate the acceptable level of uncertainty (significance level and
power) in clinical trials [45,46] and to inform development of
information that will be provided to patients during clinical trials,
including background information and study results [23].
Marketing authorization
Theuse of patient preferences in regulatorymarketing authorization
was discussed in 46 out of 113 (41%) publications. Regulatory
authorities such as the FDA [4] and the European Medicines Agency
(EMA) [1] are currently exploring the use of patient preferences [11–
13]. However, they do not require the submission of patient pre-
ferences [16]. The FDA accepts the submission of patient preference
information in approval applications for medical devices either as
supporting evidence or for informational purposes [4,47].
Patient preferences can be used at the marketing authorization
stage in benefit–risk assessment, assessment for early access [11],
and for optimizing labeling that will inform patients on benefits
and risks [3,4]. Use of patient preferences in benefit–risk assess-
ment has given rise to patient-centered benefit–risk (PCBR) assess-
ments [48,49]. Several initiatives are working on incorporating
patient preferences in benefit–risk assessments, such as the MDIC
Patient Centered Benefit-Risk Project, IMI PREFER, and the FDA’s
Center for Devices and Radiological Health (CDRH) Patient Pref-
erence Initiative [9,50]. In benefit–risk assessments, patient pre-
ferences can provide information on maximum acceptable risk,
minimum acceptable benefit, net clinical benefit, quality-adjusted
time without symptoms and toxicity, and relative value-adjusted
number needed to treat through multiple-criteria decision analy-
sis, benefit–less-risk analysis, the Gail assessment, and probabilistic
simulation methods [49,51–56]. These assessments are informed
by patient preferences through understanding the trade-offs that
patients make between benefits and risks [36]. Moreover, the
results of patient preference studies can not only show a range
of preferences, but also be used to identify subpopulations for
whom the benefits outweigh the risks [3,4,16,52,57]. Finally,
patient preferences can help to weigh the benefits and risks in
benefit–risk assessments based on the relative importance of out-
comes, benefits, and risks for the patients [51,58].
Health technology assessment & reimbursement
Although different publications described that patient preferences
can inform reimbursement decisions during the HTA and reim-Please cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
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much evidence is available on the actual use of patient preferences
in reimbursement decision making and that multiple countries do
not consider patient preferences as an explicit prioritization crite-
rion. The use of patient preferences in HTA was discussed by 49 out
of 113 (43%) publications. Although cases have been described
where HTA bodies are reluctant towards considering patient pre-
ferences in their assessments, European and US HTA bodies and
payers have increasingly shown interest in using patient prefer-
ences in their assessments (Table 2) [2,8,10,11,31,64–67].
Twelve publications specifically mentioned the use of patient
preferences in economic evaluations, including cost-effectiveness,
cost–benefit, and cost–utility analyses [60,61,68–77]. In these
analyses, patient preferences can inform the identification of
patient-relevant outcomes, and the identification of subpopula-
tions for whom the benefits outweigh the risks [20,52,61,75]. In
addition, patient preferences can help to weigh outcomes accord-
ing to their relative importance to patients [20,61,75,78]. This
could be done by incorporating patient preferences and other
evidence into a multicriteria decision analysis [52,55]. Lastly,
Bewtra et al. [76] described that the utility values resulting from
patient preference studies can be used as quality-of-life weights in
the calculation of quality-adjusted life years (QALYs). QALYs and
EuroQol five dimensions (EQ-5D) utilities are frequently used in
HTA, but their classical use has been criticized by some, because
they only cover benefit for generic quality-of-life dimensions
rather than for all factors that important to patients [73,79,80].
Post marketing
Although some applications of patient preferences described
above might also be applicable to the postmarketing phase, some
additional postmarketing-specific applications were identified in
the MDIC report [3] and the FDA guidance [4]. During the post-
marketing phase, patient preferences could inform product accep-
tance by patients, extensions of indications, postmarketing
assessments through risk weighing, and product innovation [3,4].
Factors and situations influencing the value of patient
preference studies
Many factors and situations were identified that can influence the
value of patient preference studies (Fig. 2) [18,81]. Factors were
defined by the researchers as a fact or influence that occurs during
the organization, design, conduct, or communication of results of
the study and that contribute to, or affect, the value of results from value of patient preference studies along the medical product lifecycle: a literature review,
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FIGURE 2
Factors and situations influencing the value of patient preference studies. Factors and situations were mapped along the organization, design, conduct, and
communication and use of results of patient preference studies. Stages and steps of patient preference studies and their organization were identified as they
emerged from the literature. Abbreviations: MPLC, medical product lifecycle.
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stance or condition that occurs during the use of results and that
contributes to, or affects the value of, results from patient prefer-
ence studies. Situations were considered to be external to the
preference study and not controllable by the researcher. These
factors and situations are described below following the different
stages and steps of a patient preference study. Although there are
alternative ways to describe the stages of patient preference studies
and the different steps that they encompass, we identified steps
and their organization as they emerged from the literature, in
addition to the organizational context (see SP.III in the supple-
mental information online). Stages included study design, study
conduct, and communication and use of the results.
Organizational context
Multiple organizational factors were identified that determine the
value of patient preference studies, as discussed below.
Expertise
Clinical, medical product development, patient, methodological,
and statistical expertise of the conducting parties will have con-
siderable impact on whether and how a preference study is per-
formed [2,3,12,28,30,50,82,83]. Partnerships between industry,
academia, and patient organizations can be established to acquire
the needed expertise [28], but agreements on sharing and using the
data need to be established [28,30]. Expertise must be shared
between parties to ensure appropriate conduct by trained staff
and common understanding [4,28,30].
Patient centeredness
Patient centeredness of patient preference studies is an important
factor for success. The FDA guidance [4] states that the patientPlease cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.09.015should be ‘the central focus of the study’. Patients and patient
representatives can participate in the study design to guarantee
comprehensibility of the information and questions provided to
patients, to improve recruitment, and to ensure correct interpre-
tation and communication of results [4,16,28].
Good practices
Following good research practices, similar to Good Clinical Prac-
tices [84] and Good Pharmacoepidemiology Practices [85], will
ensure a correct design and conduct of the study and the value of
the results [30,86]. However, patient preference study-specific
guidance is often lacking (Table 3). Different initiatives are work-
ing on addressing methodological issues and providing recom-
mendations and guidance on the design and conduct of patient
preference studies (Table 4).
Ethics
Compliance with ethics requirements associated with questioning
patients is necessary in setting up a patient preference study, and
differentmeasureshavetobetakentomeettheseethics requirements
[14,60]. This process is time consuming. Obtaining ethics and/or
institutional review board (IRB) approval when questioning patients
can especially be challenging for industry, and will not always give
direct access to patients and their data [31,83]. Postmus et al. [16]
described that they did not collect demographic and clinical data in
their patient preference study to avoid the complexity of data pro-
tection, but stated that not having these data limited their analysis.
Financial resources
Conducting patient preference studies comes with a financial
burden that can differ among methods. Budgets of US$100 000–
400 000 (s90 000 to s370 000) have been quoted for quantitative
patient preference studies [2,3,12,30,31,50,82,83,87]. value of patient preference studies along the medical product lifecycle: a literature review,
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TABLE 3
Availability of guidance on design and conduct of patient
preference studiesa
Topic Availability of guidance Refs
Good research practices ISPOR method-specific good
research practices
[4,78,103]
Choice of preference
exploration/elicitation method
Lack of guidance reported [3,18,98]
Selection of attributes Lack of guidance reported [3]
Whose preferences should be
measured
Lack of guidance reported [3,60]
Validity assessment Janssen et al.: Improving the
quality of discrete-choice
experiments in health: how can
we assess validity and reliability?
[109]
Lack of guidance reported [3]
a Abbreviations: ISPOR, International Society for Pharmacoeconomics and Outcomes
Research.
TABLE 4
Initiatives working on addressing methodological issues and
providing recommendations and guidance on the design and
conduct of patient preference studies
Initiative Website
IMI PREFER www.imi-prefer.eu
International Society for
Pharmacoeconomics and Outcomes
Research (ISPOR), Patient Preferences
Special Interest Group
www.ispor.org/sigs/
Stated-Preference-Methods.asp
International Academy of Health
Preference Research (IAHPR)
http://iahpr.org
International Health Economics Association
(iHEA), Health Preference Research Special
Interest Group
www.healtheconomics.org/
page/HealthPreference
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The conduct of a patient preference study is time-consuming,
ranging from 6 months to 2 years in complex cases
[2,12,30,82,83]. The recruitment of patients can particularly take
more time than is anticipated [82,83].
Timing along MPLC
It is not clear when patient preference studies should be conducted
because the submission of patient preferences is currently not
required by regulatory authorities and HTA bodies and/or payers,
but can be accepted as supporting evidence in a submission dossier
[3,4,50,55]. Currently, the study sponsor themselves needs to
decide whether information on patient preferences is needed
and to assess when and how to best collect it [3].
Patient preference study design
If patient preferences are elicited in well-designed and well-con-
ducted patient preference studies, patient preferences are consid-
ered to be valid scientific evidence that can be valuable in
informing decision making [4]. Thus, the design phase of a patient
preference study is a crucial phase. Inadequate design will nega-
tively influence the value of the study and make it unlikely that
outcomes will be considered by decision makers [12]. Design
factors that could influence the value of the study are discussed
below per step in the design process (Fig. 2).Please cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
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The formulation of the research question will influence the value
of the study and choice of preference elicitation, or exploration
method, because the applicability of measuring patient prefer-
ences depends on the research question being asked [3,30]:
Patient versus other preferences
Decision making might not be sensitive to patient preferences
when preferences of other stakeholders, such as the general public
or clinicians, or other evidence, are found to be more important
than those of the patient [3]. This might be particularly important
when setting up a study to inform HTA because some reimburse-
ment decision-makers might wish to take the preferences of the
general public, as a healthcare payer, into account [55,63,88].
Sample definition
Besides obtaining ethics and/or IRB approval and access to patients
as described above, additional factors can influence the value of
patient preference studies during sample definition:
Clarity
Clearly defining the patient sample will ensure inclusion of the
right patients and value of results. Setting up inclusion and
exclusion criteria can safeguard a clear definition of the patient
sample [3].
Ensuring representativeness
Ensuring heterogeneity in the patient sample will result in gener-
alizable results that are representative of the preferences of the full
patient population for which the medical product is intended to be
launched [3,4,21,30,36,50,89,90]. Generalizability of the results
might be limited because of the eligibility criteria of the sample,
especially when patient preference studies are performed along-
side clinical trials [39,72,89,91–96].
Ability to participate
In the following patient populations, it might be more difficult to
measure preferences and it might be necessary to pay more attention
to the design of the exploration or elicitation instrument: (i) low
reading level or vision difficulties; (ii) not able to use a pencil or a
computer mouse; (iii) no access to the internet; (iv) physically
disabled; (v) cognitive impairments; and (vi) pediatric patient popu-
lations [3,4,70,83,97]. If preferences cannot be elicited directly from
patients themselves, preferences can be elicited from informal care-
givers, including parents and family members [3,4,33]. Parents can
be included to represent their children and family members to
represent older relatives [3,4,30,49,70,93,98]. However, their pre-
ferences might differ from those of the patients because they might
not assign the same values to various risks and benefits [4,99].
Sample size
During the design phase of patient preference studies, sample size
and power calculations can be made to allow for statistical analyses
later on [14,100]. If sample size calculations do not take heteroge-
neity into account, it might be impossible to do subpopulations
analysis when results are available [89,90,93,95,97]. Required
sample sizes differ among methods. For example, in general,
smaller samples are required for swing weighting compared with
DCEs [87].
Method selection
Many different types of preference exploration (qualitative) and
elicitation (quantitative) methods exist and can be used in patient value of patient preference studies along the medical product lifecycle: a literature review,
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patient preference studies are discussed below.
Match to research question
The optimal method for patient preference elicitation or explora-
tion will depend on the study objective and primary use of results,
and can be discussed with the stakeholders affected by, or evalu-
ating, the results in advance to increase the value of the study
[4,12,18,81,101]. Elicitation methods can quantify personal pre-
ferences, are structured, have clearly defined data types, have
limited response options, allow for statistical analysis, and are
recommended to be used when the aim is to explore preference
heterogeneity in different patient profiles [3,4,45,56]. Exploration
methods, such as interviews and focus groups, are recommended
for concept exploration and gaining in-depth knowledge of the
value of medical products [3,10,18]. Although it is important to
match the method to the research question, this specificity and
lack of standard measures is also what makes it hard to compare
preference studies across conditions, limiting their value for some
HTA agencies or reimbursement decision-makers [55].
Match to MPLC stage
The appropriate choice of the method depends on the phase in the
MPLC. During discovery, interactive exploration methods, such as
focus groups, have been described as being particularly useful [4].
In informing clinical trial design, both exploration and elicitation
methods have been used [24,25,35–37,39,102]. For benefit–risk
assessments, elicitation methods, such as DCE and AHP, as well as
exploration methods can be useful [12,53,59,103]. In HTA, elici-
tation methods that can examine willingness to pay are also
described as being useful [59,60,69,70,81,104,105]. However, until
now, HTA has mainly focused on patient involvement using
preference exploration methods [55,106,107].
Validity of the method
Given that participant responses might depend on the preference
elicitation method used [105,108], weights or values obtained
throughdifferentmethodsmightnotbecomparable [82]. Therefore,
guidance on which methods to use are of important to ensure the
value of patient preference studies in decision making. There is a lack
of guidance on how to assess the validity of a patient preference
study [3] (Box 5). However, work is underway onapproachesto assess
the validity of patient preference studies. For example, Janssen et al.
[109] created a conceptual model for the assessment of validity in
DCEs. The manner in which internal validity can be ensured or
assessed depends on the method used. Tervonen et al. [87] compared
swing weighting (SW) to DCEs and stated that internal validity is
automatically enforced with SW because of the exact nature of the
collected preferences, whereas the internal validity of DCE results
needs to be assessed manually. Assessment of external validity of
stated-preference methods, requiring a comparison between stated
and actual choices, is difficult to perform because of the use of
hypothetical choices [3,100].
Instrument design
Depending on the objective of a patient preference study, the
preference exploration or elicitation instrument can be designed
to explore or elicit preferences for health states, treatment attri-
butes, or treatment alternatives [81]. Different factors related to
the design of the instrument influence the value of the study, as
discussed below.Please cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.09.015Capturing demographics and clinical baseline data
Collecting demographic and clinical data is important if subgroup
analysis is planned to be performed [16].
Attribute development
Attributes could be identified through patient and caregiver in-
volvement, via a combination of literature reviews, interviews,
and meta-analyses of clinical data, and possibly via trial economic
evaluations [49,73,89,110]. Identifying attributes and their levels
that are relevant and do not overlap is necessary to produce results
that can be used to assess trade-offs [4,16,49]. When the real-life
attributes and levels are not sufficiently different and do overlap,
hypothetical choices can be included. This inclusion is often
mentioned as a limitation, because hypothetical choices can
reflect benefit and risk profiles other than of the actual therapies
that will be approved [3,36,91,93,96]. The number of attributes
that can be included in the instrument differs among methods. For
example, DCEs have been argued to not allow the inclusion of
many attributes and, thus, their applicability to contexts with
many attributes is limited [87].
Cognitive burden
Cognitive burden varies among methods, and minimization of this
burden will assure the value of the results [4,87]. In patient prefer-
ence elicitation studies, the cognitive burden for participants can be
high becauseof the useof hypothetical choicesand the largenumber
and representation of questions, attributes, and levels
[3,4,14,52,59,82,83,89,91,111]. Exploration methods, including
interviews and focus group discussions, have a low cognitive burden
for participants [61]. The patient population should be able to
perform the method-specific tasks and understand the questions
to realize results that can be used to assess meaningful trade-offs
[3,4,16,49,83,112]. Survey administration via interviews or work-
shops instead of online administration could provide support to
patients in understanding the questions [87,112].
Patient education
The extent to which patients are informed on the benefits and risks
of the medical product when participating in a patient preference
study is a determining factor for the value of the results [4,16].
Effective communication on benefits, risk, uncertainties, and
probabilities [30] can overcome cognitive burden [96] through
the use of appropriate numeric, verbal, and graphic representa-
tions [4,52,82]. Effective communication is especially important
when the instrument is designed on a self-administered basis
[4,30]. The amount of, and how, information is provided to
patients on the disease, risks, and benefits can influence their
preferences and the validity of the study
[24,30,63,83,98,110,11–115]. In describing outcomes to patients,
Hockley et al. [83] recommend defining the name of the outcome,
the description, recurrence, duration, and whether the outcome is
treatable. Although no further guidance on patient education in
patient preference studies was found, other sources that might
provide information on how to educate patients include the
guidance of the FDA on communicating benefits and risks
[116], the IMI EUPATI project [117], and the criteria for judging
the quality of patient decision aids from the International Patient
Decision Aid Standards (IPDAS) [118].
Question framing
When eliciting patient preferences, the framing of the questions
can influence preferences and the validity of the study [119,120]. value of patient preference studies along the medical product lifecycle: a literature review,
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preferences for treatment are difficult to measure because of the
large influence of question framing and presentation effects (posi-
tive/negative question wording biases)’. In addition, Howard et al.
[120] demonstrated in a DCE study that attribute framing can
influence patient preferences.
Appeal of the instrument
The selection of a method and design of the instrument can
depend on how engaging the instrument is to prevent dropout.
Minimal dropout can be achieved when the instrument is engag-
ing through inclusion of engaging stimuli and exclusion of com-
plex formats and difficult to answer questions [3,83].
Patient preference study conduct
Relevant factors influencing the value of the study and related to
the study conduct are discussed below, based on each step of study
conduct (Fig. 2).
Participant recruitment
Besides obtaining ethics and/or IRB approval and access to
patients, as described above, another factor related to the recruit-
ment of participants that will influence the value of the study is
representativeness. Obtaining a representative sample of the pa-
tient population is a recruitment challenge for many patient
preference studies [2,100]. Sample bias can be caused by over-
inclusion of motivated patients, for example because of the re-
cruitment of patients via a sole patient organization
[16,36,49,78,93,121]. However, even in case of sample bias, the
results of patient preference studies might still be meaningful for
subpopulations [16].
Piloting and data collection
Testing validity and reliability
Performing pilot studies before the main data collection is done
will allow testing of validity and reliability of the preference
method and instrument [78,83].
Protocol compliance
During data collection, compliance with the protocol is a crucial
determinant of the validity and reliability of the results [4,30].
Analysis and interpretation
Robustness
When the robustness of the analysis is ensured, results of the
analysis will lead to appropriate interpretation [4,30]. However,
the value of the analysis can be reduced if the design of the study
was not well set up [82]. In quantitative patient preference studies,
statistical analysis can be performed, resulting in estimates and
uncertainties (confidence intervals or standard errors), which can
create a value model [4,16,33]. A sensitivity analysis can be per-
formed to assess the importance of the different values in the
model [4,33]. It might be necessary to use advanced regression
techniques in quantitative patient preference studies, such as the
mixed logit model [89,93]. For qualitative patient preference
studies, statistical analysis is not appropriate [92].
Preference heterogeneity
Given that individual preferences are measured in patient prefer-
ence studies, it is possible that there are differences between
patients in how they perceive and weigh the attributesPlease cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.09.015
8 www.drugdiscoverytoday.com[4,50,60,95,122]. Some patients might accept higher risks for a
certain benefit than other patients [3,4,50]. The detection of these
differences could not only reveal population-level preferences for
the medical product, but might also lead to the identification of
subpopulations tolerating the risks [3,4,50,52,62]. Using statistical
analysis tools that allow for detection of variation and distribution
of preferences, for example latent class analysis, makes subgroup
analysis possible [48,78,89,123]. However, the number of sub-
groups that can be evaluated is limited [48]. Allowing for the
identification of subpopulations for whom the benefits outweigh
the risks will increase the value of the study for benefit–risk
assessments and HTA [3,4,16,20,52,57].
Communication and use of the results from patient
preference studies
The results of patient preferences studies can be communicated to,
and used by, different stakeholders in decision making during the
MPLC. Besides the communication of results to stakeholders for
use in decision making, results can also be communicated back to
patients. However, the communication of results to patients
should be done in a different manner than communication to
assessors. During the use of the results, stakeholders’ attitudes
toward the use of patient preferences, but also clinical and market
situations can influence the value of patient preferences studies.
Factors arising in communication of results
Tailoring of communication
Results of patient preference studies can inform many stake-
holders, including industry, regulators, HTA bodies, payers, phy-
sicians, patient organizations, and patients. However, these
stakeholders have different needs and, therefore, tailoring of the
language, format, and venue of the study results to the stakeholder
group can enhance the value of the results to the stakeholders.
Patient organizations can participate in the communication of
results to patients to ensure comprehensibility of the disseminated
results [28].
Presentation of results
Visualizing results can prevent their misinterpretation, and can be
achieved through the use of tables, forest plots, and bar charts [82].
Situations influencing the value of patient preference studies
Patient population characteristics
Patient preferences might be especially useful in a population with
unmet medical needs or in rare diseases [3,4,49]. However, if the
medical product is developed for an unmet medical need with
severe symptoms and high mortality, or if the outcomes of treat-
ment with the medical product are more favorable than the out-
comes of the disease treated with best-available care, it might be
less valuable to elicit patient preferences [3].
Product characteristics
The characteristics of the investigational product and its alterna-
tives influence the value of patient preferences in decision making
[3,4,50]. Patient preferences can be useful for decision making
when: (i) it concerns a self-use medical product; (ii) there are
significant benefits and risks compared with alternatives; (iii) there
are different alternatives with different profiles (preference-sen-
sitive situations); (iv) the importance of the benefits and risks is
similar (uncertain benefit–risk profiles); (v) benefits and harms do value of patient preference studies along the medical product lifecycle: a literature review,
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disease area are used; (vii) risks can be identified for which no
benefit can compensate; and (viii) clinical experiences and end-
points are subjective [3,4,45,50,89,105,110]. When approval is
likely because of important benefits and nonsevere risks or because
of superiority compared with alternatives, patient preferences
might become less valuable [3].
Familiarity of assessors
Eliciting patient preferences might be especially valuable in pa-
tient populations with which regulators are not familiar [50].
When sponsors and regulators know the disease area and technol-
ogies well, patient preferences become less valuable [3]. In addi-
tion, the value of elicited quantitative patient preferences for
decision making can be limited by unfamiliarity with preference
methods among assessors interpreting the results [82,98].
Attitudes of assessors
There is no consensus on the role of patient preferences in decision
making along the MPLC. A consensus on this role might be
difficult to achieve because of distrust in the use of patient pre-
ferences resulting from the false impression that preferences can
only be used as averages, fear that patient preferences will replace
existing clinical evidence, barriers to ‘cultural change’, the lack of
consensus on the definition of patient preferences, and disap-
pointment risk (i.e., the possibility that patient preference studies
might yield unexpected results; e.g., some patients might not want
to accept the risks of a new product)
[1,3,4,12,30,31,36,47,50,63,64,66,70,81–83,98,124,125].
New competitors
If new treatment options become available, or if new benefits and
risks are identified, the results of previously performed patient
preference studies might no longer be valid and might need to be
reconducted [82].
Concluding remarks
Although limited evidence was found on the actual use of patient
preferences in decision making, they are gaining attention in
processes along the MPLC. We believe that additional guidance
on the use of patient preferences in assessments and decision
making is necessary to increase their use. Moreover, use of patient
preferences could increase if regulatory authorities, HTA bodies,
and payers would inform the industry about whether and how
they would use patient preferences in their processes, or would
state in what situations they find patient preferences valuable or
even require the submission of results from patient preference
studies.
Many factors and situations have to be taken into account when
designing and conducting a patient preference study to obtainPlease cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.09.015valuable results that can be used in assessments and decision
making. The main trends among the factors that we described
here that will contribute to the value of a patient preference study
are: (i) having a multidisciplinary team; (ii) ensuring patient
centeredness in the design as well as the conduct and communi-
cation of results; (iii) matching the sample and the method to the
research question; (iv) safeguarding validity in the method selec-
tion and instrument design; (v) reducing cognitive burden; (vi)
providing adequate patient education; (vii) guaranteeing that
preference heterogeneity can be measured and interpreted; and
(viii) tailoring communication of results to the audience. Further
research should focus on validating these results through the
exploration of stakeholder perspectives and by conducting patient
preference studies.
Competing interests
The Patient Preferences in Benefit-Risk Assessments during the
Drug Life Cycle (PREFER) project has received funding from the
Innovative Medicines Initiative 2 Joint Undertaking under grant
agreement No 115966. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation
programme and EFPIA. This text and its contents reflects the
PREFER project’s view and not the view of IMI, the European
Union or EFPIA. J.J. declares the following competing interests:
employee of Sanofi, a global biopharmaceutical company focused
on human health; and ownership of shares in Sanofi. B.L. declares
the following competing interests: employee of Janssen Research
and Development, LLC; and stockholder in Johnson & Johnson
and in a portfolio that at times includes other pharmaceutical and
health care-related companies. J.K. declares the following compet-
ing interests: representing CSL Behring on IMI PREFER; scientific
consultant working for the pharmaceutical industry; and stock-
holder in a portfolio that includes pharmaceutical and health care-
related companies.
Acknowledgments
The authors would like to thank all members of the PREFER project
for their input and support during the conduct of this literature
review. A special thanks to Judith Gulpers from Erasmus University
Rotterdam who helped refining and running the search queries.
Furthermore, the authors are indebted to the anonymous
reviewers for their insights and suggestions.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.drudis.2018.09.
015.References1 EMA (2013) The Patient’s Voice in the Evaluation of Medicines. EMA
2 Abelson, J. et al. (2016) Public and patient involvement in health technology
assessment: a framework for action. Int. J. Technol. Assess. Health Care 32, 256–264
3 MDIC (2015) Patient Centered Benefit–Risk Project Report: A Framework for Incorporating
Information on Patient Preferences regarding Benefit and Risk into Regulatory Assessments
of New Medical Technology. MDIC
4 Anon (2016) Patient Preference Information – Voluntary Submission, Review in Premarket
Approval Applications, Humanitarian Device Exemption Applications, and De Novo
Requests, and Inclusion in Decision Summaries and Device Labeling: Guidance for Industry,Food and Drug Administration Staff, and Other Stakeholders. US Department of Health
and Human Services, FDA, Center for Devices and Radiological Health and Center for
Biologics Evaluation and Research
5 Meredithm, Y.S. et al. (2016) Patient engagement at a tipping point—the need for
cultural change across patient, sponsor, and regulator stakeholders: insights from the
DIA conference, ‘Patient Engagement in Benefit Risk Assessment Throughout the Life
Cycle of Medical Products’. Ther. Innov. Regul. Sci. 50, 546–553
6 Soekhai, V. et al. (2017) Compendium of methods for measuring patient preferences
in medical treatment. Value Health 20, A684–A685 value of patient preference studies along the medical product lifecycle: a literature review,
www.drugdiscoverytoday.com 9
REVIEWS Drug Discovery Today Volume 00, Number 00 October 2018
DRUDIS-2320; No of Pages 12
Review
s
FO
U
N
D
A
TIO
N
R
EV
IEW7 MDCI (2015) Medical Device Innovation Consortium (MDIC) Patient Centered Benefit–
Risk Project (PCBR): Appendix A: Catalog of Methods for Assessing Patient Preferences for
Benefits and Harms of Medical Technologies. MDIC
8 EPF (2013) Patient Involvement in Health Technology Assessment in Europe: Results of the
EPF Survey. EPF
9 de Bekker-Grob, E.W. et al. (2017) Giving Patients’ preferences a voice in medical
treatment life cycle: the PREFER Public–Private Project. Patient 10, 263–266
10 Facey, K. et al. (2010) Patients’ perspectives in health technology assessment: a route to
robust evidence and fair deliberation. Int. J. Technol. Assess. Health Care 26, 334–340
11 Breckenridge, A. (2011) Patient opinions and preferences in drug development and
regulatory decision making. Drug Discov. Today Technol. 8, e11–e14
12 van Til, J.A. and Ijzerman, M.J. (2014) Why should regulators consider using patient
preferences in benefit-risk assessment? Pharmacoeconomics 32, 1–4
13 Menon, D. et al. (2014) Involving patients in reducing decision uncertainties around
orphan and ultra-orphan drugs: a rare opportunity? Patient 8, 29–39
14 Hockley, K. et al. (2014) Study Protocol: Eliciting Patient Preferences on the Benefits and
Risks of Treatments for Relapsing Remitting Multiple Sclerosis. IMI
15 Mol, P.G. et al. (2015) Understanding drug preferences, different perspectives. Br. J.
Clin. Pharmacol. 79, 978–987
16 Postmus, D. et al. (2016) Incorporating patient preferences into drug development
and regulatory decision making: Results from a quantitative pilot study with cancer
patients, carers, and regulators. Clin. Pharmacol. Ther. 99, 548–554
17 Mt-Isa, S. et al. (2014) Balancing benefit and risk of medicines: a systematic review
and classification of available methodologies. Pharmacoepidemiol. Drug Saf. 23, 667–
678
18 Egbrink, M.O. and IJzerman, M. (2014) The value of quantitative patient preferences
in regulatory benefit–risk assessment. J. Mark. Access. Health Policy 2, 1http://dx.doi.
org/10.3402/jmahp.v2.22761
19 Menon, D. and Stafinski, T. (2011) Role of patient and public participation in health
technology assessment and coverage decisions. Expert Rev. Pharmacoecon. Outcomes
Res. 11, 75–89
20 Kievit, W. et al. (2017) Taking patient heterogeneity and preferences into account in
health technology assessments. Int. J. Technol. Assess. Health Care 33, 562–569
21 Gaudiano, B.A. et al. (2013) Patients’ treatment expectancies in clinical trials of
antidepressants versus psychotherapy for depression: a study using hypothetical
vignettes. Compr. Psychiatry 54, 28–33
22 Bloom, D. et al. (2018) The rules of engagement: CTTI recommendations for
successful collaborations between sponsors and patient groups around clinical
trials. Ther. Innov. Regul. Sci. 52, 206–213
23 Lim, S.S. et al. (2017) Simulating clinical trial visits yields patient insights into study
design and recruitment. Patient Prefer. Adherence 11, 1295–1307
24 Franco, M.R. et al. (2013) Methodological limitations prevent definitive conclusions
on the effects of patients’ preferences in randomized clinical trials evaluating
musculoskeletal conditions. J. Clin. Epidemiol. 66, 586–598
25 Marcus, S.M. et al. (2012) Estimating the causal effect of randomization versus
treatment preference in a doubly randomized preference trial. Psychol. Methods 17,
244–254
26 Utens, C.M.A. et al. (2014) The use of research evidence on patient preferences in
pharmaceutical coverage decisions and clinical practice guideline development:
exploratory study into current state of play and potential barriers. BMC Health Serv.
Res. 14, 540
27 Levitan, B. et al. (2017) The ball is in your court: agenda for research to advance the
science of patient preferences in the regulatory review of medical devices in the
United States. Patient 10, 531–536
28 Wolka, A.M. et al. (2017) Effective partnering in conducting benefit-risk patient
preference studies: perspectives from a patient advocacy organization, a
pharmaceutical company, and academic stated-preference researchers. Ther. Innov.
Regul. Sci. 52 (4), 507–513
29 Marsh, K. (2016) Incorporating Patient Preferences into Product Development and Value
Communication: Why, When and How? The Evidence Forum
30 Selig, W.K.D. (2016) Key Considerations for Developing & Integrating Patient Perspectives
in Drug Development: Examination of the Duchenne Case Study. Biotechnology
Innovation Organization
31 Lowe, M.M. et al. (2016) Increasing patient involvement in drug development.
Value Health 19, 869–878
32 Cross, J. et al. (2016) Caregiver preferences for the treatment of males with fragile X
syndrome. J. Dev. Behav. Pediatr. 37, 71–79
33 Morel, T. et al. (2016) Quantifying benefit–risk preferences for new medicines in rare
disease patients and caregivers. Orphanet. J. Rare Dis. 11, 70
34 Stewart, K.D. et al. (2016) Preference for pharmaceutical formulation and treatment
process attributes. Patient Prefer. Adherence 10, 1385–1399
35 Ervin, C.M. et al. (2014) Assessment of treatment response in chronic constipation
clinical trials. Clin. Exp. Gastroenterol. 7, 191–198Please cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.09.015
10 www.drugdiscoverytoday.com36 Minion, L.E. et al. (2016) Endpoints in clinical trials: what do patients consider
important? A survey of the Ovarian Cancer National Alliance. Gynecol. Oncol. 140,
193–198
37 Stamuli, E. et al. (2017) Identifying the primary outcome for a randomised
controlled trial in rheumatoid arthritis: the role of a discrete choice experiment. J.
Foot Ankle Res. 10, 57
38 Walter, S.D. et al. (2017) Estimation of treatment preference effects in clinical trials
when some participants are indifferent to treatment choice. BMC Med. Res.
Methodol. 17, 29
39 Gryczynski, J. et al. (2013) Patient perspectives on choosing buprenorphine over
methadone in an urban, equal-access system. Am. J. Addict. 22, 285–291
40 Olschewski, M. et al. (1992) Analysis of randomized and nonrandomized patients in
clinical trials using the comprehensive cohort follow-up study design. Control Clin.
Trials 1, 226–239
41 King, M. et al. (2005) Conceptual framework and systematic review of the effects of
participants’ and professionals’ preferences in randomised controlled trials. Health
Technol. Assess. 9, 1–186
42 Preference Collaborative Review Group (2008) Patients’ preferences within
randomised trials: systematic review and patient level meta-analysis. BMJ 337,
a1864
43 Johnson, R.E. et al. (2007) Active exercise, education, and cognitive behavioral
therapy for persistent disabling low back pain: a randomized controlled trial. Spine
32, 1578–1585
44 George, S.Z. and Robinson, M.E. (2010) Preference, expectation, and satisfaction in
a clinical trial of behavioral interventions for acute and sub-acute low back pain. J.
Pain 11, 1074–1082
45 Chaudhuri, S.E. et al. (2018) Patient-centered clinical trials. Drug Discov. Today 23,
395–401
46 Montazerhodjat, V. et al. (2017) Use of Bayesian decision analysis to minimize harm
in patient-centered randomized clinical trials in oncology. JAMA Oncol. 3 (9),
e170123http://dx.doi.org/10.1001/jamaoncol.2017.0123
47 Anon (2016) Patient Perspective Value Framework (PPVF): Draft Methodology. Avalere
and Milken Institute
48 Janssen, E.M. et al. (2017) Education and patient preferences for treating type 2
diabetes: a stratified discrete-choice experiment. Patient Prefer. Adherence 11, 1729–
1736
49 Hollin, I.L. et al. (2017) Patient-centered benefit-risk assessment in Duchenne
Muscular Dystrophy. Muscle Nerve 5, 626–634
50 Ho, M. et al. (2016) A framework for incorporating patient preferences regarding
benefits and risks into regulatory assessment of medical technologies. Value Health
19, 746–750
51 Marsh, K. et al. (2017) Amplifying each patient’s voice: a systematic review of multi-
criteria decision analyses involving patients. Appl. Health Econ. Health Policy 15, 155–
162
52 Marsh, K. et al. (2018) Patient-centered decision making: lessons from multi-criteria
decision analysis for quantifying patient preferences. Int. J. Technol. Assess. Health
Care 34, 105–110
53 Hauber, A.B. et al. (2013) Quantifying benefit-risk preferences for medical
interventions: an overview of a growing empirical literature. Appl. Health Econ.
Health Policy 11, 319–329
54 Marrone, A.K. et al. (2017) The regulatory perspectives on endoscopic devices for
obesity. Gastrointest. Endosc. Clin. N. Am. 27 (2), 327–341http://dx.doi.org/10.1016/
j.giec.2016.12.004
55 Mott, D.J. (2018) Incorporating quantitative patient preference data into
healthcare decision making processes: is HTA falling behind? Patient XX, YYY–
ZZZ
56 Puhan, M.A. et al. (2012) A framework for organizing and selecting quantitative
approaches for benefit–harm assessment. BMC Med. Res. Methodol. 12, 173
57 Irony, T. et al. (2016) Incorporating patient preferences into medical device benefit-
risk assessments. Stat. Biopharm. Res. 8, 230–236
58 Puhan, M.A. et al. (2015) Quantitative benefit–harm assessment for setting research
priorities: the example of roflumilast for patients with COPD. BMC Med. 13, 157
59 Weernink, M.G.M. et al. (2014) A systematic review to identify the use of preference
elicitation methods in healthcare decision making. Pharm. Med. 28, 175–185
60 Mott, D.J. and Najafzadeh, M. (2016) Whose preferences should be elicited for use in
health-care decision-making? A case study using anticoagulant therapy. Expert Rev.
Pharmacoecon. Outcomes Res. 16, 33–39
61 IQWiG (2013) Analytic Hierarchy Process (AHP) – Pilot Project to Elicit Patient Preferences
in the Indication ‘Depression’. IQWiG
62 IQWiG (2014) Choice-Based Conjoint Analysis – Pilot Project to Identify, Weight, and
Prioritize Multiple Attributes in the Indication ‘Hepatitis C’. IQWiG value of patient preference studies along the medical product lifecycle: a literature review,
Drug Discovery Today Volume 00, Number 00 October 2018 REVIEWS
DRUDIS-2320; No of Pages 12
Re
vi
ew
s
 F
O
U
N
D
A
TI
O
N
R
EV
IE
W63 Dirksen, C.D. (2014) The use of research evidence on patient preferences in health
care decision-making: issues, controversies and moving forward. Expert Rev.
Pharmacoecon. Outcomes Res. 14, 785–794
64 Moes, F. et al. (2017) Contested evidence: a Dutch reimbursement decision taken to
court. Health Econ. Policy Law 12, 325–344
65 Pisa, G. (2015) A Step Towards Patient-Centricity: Analysis of HTA Requirements for
Patient Preference Data Collection in Germany. Kantar Health
66 Mu¨hlbacher, A.C. et al. (2016) Patient-focused benefit-risk analysis to inform
regulatory decisions: the European Union perspective. Value Health 19, 734–740
67 Hailey, D. et al. (2013) Involvement of consumers in health technology assessment
activities by Inahta agencies. Int. J. Technol. Assess. Health Care 29, 79–83
68 Bilvick Tai, B.W. et al. (2016) A systematic review of health economic evaluation
studies using the patient’s perspective. Value Health 19, 903–908
69 Rodriguez, J.M. et al. (2011) The use of quality-adjusted life-years in the economic
evaluation of health technologies in Spain: a review of the 1990–2009 literature.
Value Health 14, 458–464
70 Thebaut, C. (2013) Dealing with moral dilemma raised by adaptive preferences in
health technology assessment: the example of growth hormones and bilateral
cochlear implants. Soc. Sci. Med. 99, 102109
71 Terris-Prestholt, F. et al. (2016) Parameterising user uptake in economic evaluations:
the role of discrete choice experiments. Health Econ. 25 (Suppl. 1), 116–123
72 Martin-Fernandez, J. et al. (2014) Willingness to pay for a quality-adjusted life year:
an evaluation of attitudes towards risk and preferences. BMC Health Serv. Res. 14, 287
73 Tinelli, M. et al. (2016) What, who and when? Incorporating a discrete choice
experiment into an economic evaluation. Health Econ. Rev. 6, 31
74 Goto, D. et al. (2017) Regression-based approaches to patient-centered cost-
effectiveness analysis. PharmacoEconomics 35, 685–695
75 Muhlbacher, A.C. and Sadler, A. (2017) The probabilistic efficiency frontier: a
framework for cost-effectiveness analysis in Germany put into practice for Hepatitis
C treatment options. Value Health 20, 266–272
76 Bewtra, M. and Johnson, F.R. (2013) Assessing patient preferences for treatment
options and process of care in inflammatory bowel disease: a critical review of
quantitative data. Patient 6, 241–255
77 Finnell, S.M.E. et al. (2012) Application of classic utilities to published pediatric cost-
utility studies. Acad. Pediatr. 12, 219–228
78 Mu¨hlbacher, A.C. et al. (2017) Preferences for antiviral therapy of chronic hepatitis
C: a discrete choice experiment. Eur. J. Health Econ. 18, 155–165
79 Kay, S. and Ferreira, A. (2014) Mapping the 25-item national eye institute visual
functioning questionnaire (NEI VFQ-25) to EQ-5D utility scores. Ophthal. Epidemiol.
21, 66–78
80 Beresniak, A. et al. (2015) Validation of the underlying assumptions of the quality-
adjusted life-years outcome: results from the ECHOUTCOME European project.
Pharmacoeconomics 33, 61–69
81 Gutknecht, M. et al. (2016) A systematic review on methods used to evaluate patient
preferences in psoriasis treatments. J. Eur. Acad. Dermatol. Venereol. 30, 1454–1464
82 Hughes, D. et al. (2013) Recommendations for the Methodology and Visualisation
Techniques to be Used in the Assessment of Benefit and Risk of Medicines. IMI
83 Hockley, K. et al. (2013) Patient and Public Involvement Report: Recommendations for
Patient and Public Involvement in the Assessment of Benefit and Risk of Medicines. IMI
84 ICH (2016) Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6
(R2). International Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use (ICH). ICH
85 Public Policy Committee, and International Society of Pharmacoepidemiology,
(2016) Guidelines for good pharmacoepidemiology practice (GPP).
Pharmacoepidemiol. Drug Saf. 25, 2–10
86 Torgerson, D.J. et al. (1996) Patient preferences in randomised trials: threat or
opportunity? J. Health Serv. Res. Policy 1, 194–197
87 Tervonen, T. et al. (2017) MCDA swing weighting and discrete choice experiments
for elicitation of patient benefit-risk preferences: a critical assessment.
Pharmacoepidemiol. Drug Saf. 26, 1483–1491
88 Janssen, I.M. et al. (2016) Importance of hemodialysis-related outcomes:
comparison of ratings by a self-help group, clinicians, and health technology
assessment authors with those by a large reference group of patients. Patient Prefer.
Adherence 10, 2491–2500
89 Tinelli, M. et al. (2012) What determines patient preferences for treating low risk
basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice
experiment survey from the SINS trial. BMC Dermatol. 12, 19http://dx.doi.org/
10.1186/1471-5945-12-19
90 Gries, K.S. et al. (2016) Preferences for prostate cancer outcomes: a comparison of
the patient perspective, the general population perspective, and a population at risk
for prostate cancer. Value Health 19, 218–225Please cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.09.01591 Katz, E.G. et al. (2016) Physician and patient benefit-risk preferences from two
randomized long-acting injectable antipsychotic trials. Patient Prefer. Adherence 10,
2127–2139
92 Svedsater, H. et al. (2013) Qualitative assessment of attributes and ease of use of the
ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and
COPD. BMC Pulmon. Med. 13, 72http://dx.doi.org/10.1186/1471-2466-13-72
93 Peay, H.L. et al. (2014) A community-engaged approach to quantifying caregiver
preferences for the benefits and risks of emerging therapies for Duchenne muscular
dystrophy. Clin. Ther. 36, 624–637
94 Roy, A.N. et al. (2015) A discrete choice experiment to elicit patient willingness to
pay for attributes of treatment-induced symptom relief in comorbid insomnia.
Manag. Care 24, 42–48
95 Silverman, S. et al. (2013) Patient weighting of osteoporosis medication attributes
across racial and ethnic groups: a study of osteoporosis medication preferences
using conjoint analysis. Osteoporosis Int. 24, 2067–2077
96 Ho, M.P. et al. (2015) Incorporating patient-preference evidence into regulatory
decision making. Surg. Endosc. 29, 2984–2993
97 Nafees, B. et al. (2016) Managing neurogenic bowel dysfunction: what do patients
prefer? A discrete choice experiment of patient preferences for transanal irrigation
and standard bowel management. Patient Prefer. Adherence 10, 195–204
98 Smith, M.Y. et al. (2016) Patient engagement at a tipping point—the need for
cultural change across patient, sponsor, and regulator stakeholders: insights from
the DIA conference, ‘Patient Engagement in Benefit Risk Assessment Throughout
the Life Cycle of Medical Products’. Ther. Innov. Regul. Sci. 50, 546–553
99 Faggioli, G. et al. (2011) Preferences of patients, their family caregivers and vascular
surgeons in the choice of abdominal aortic aneurysms treatment options: the
PREFER study. Eur. J. Vasc. Endovasc. Surg. 42, 26–34
100 Gonzalez, J.M. et al. (2017) Patient and physician preferences for anticancer drugs
for the treatment of metastatic colorectal cancer: a discrete-choice experiment.
Cancer Manag. Res. 9, 149–158
101 Gold, D.T. et al. (2011) Development, reliability, and validity of a new preference
and satisfaction questionnaire. Value Health 14, 1109–1116
102 Stewart, M.J. et al. (2008) Patient and clinician treatment preferences do not
moderate the effect of exercise treatment in chronic whiplash-associated disorders.
Eur. J. Pain 12, 879–885
103 Johnson, F.R. and Zhou, M. (2016) Patient preferences in regulatory benefit-risk
assessments: a US perspective. Value Health 19, 741–745
104 Sa´nchez Martı´nez, F.I., Pinto Prades, J.L., Abella´n Perpin˜a´n, J.M., Martı´nez Pe´rez, J.
E. The role of non-transparent matching methods in avoiding preference reversals in the
evaluation of health outcomes, Published online. [cited 15 May 2017]. Available
from: http://www.revecap.com/encuentros/trabajos/s/pdf/193.pdf.
105 MacLean, S. et al. (2012) Patient values and preferences in decision making for
antithrombotic therapy: a systematic review: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines. Chest 141 (2 Suppl), e1S–e23S
106 Gagnon, M.P. et al. (2011) Introducing patients’ and the public’s perspectives to
health technology assessment: a systematic review of international experiences.
Int. J. Technol. Assess. Health Care 27, 31–42
107 Kleme, J. et al. (2014) Patient perspective in health technology assessment of
pharmaceuticals in Finland. Int. J. Technol. Assess. Health Care 30, 306–311
108 Ijzerman, M.J. et al. (2012) A comparison of analytic hierarchy process and
conjoint analysis methods in assessing treatment alternatives for stroke
rehabilitation. Patient 5, 45–56
109 Janssen, E.M. et al. (2017) Improving the quality of discrete-choice experiments in
health: how can we assess validity and reliability? Expert Rev. Pharmacoecon.
Outcomes Res. 17, 531–542
110 Swinburn, P. et al. (2011) Preferences for antimuscarinic therapy for overactive
bladder. BJU Int. 108, 868–873
111 Eliasson, L. et al. (2017) Evaluation of psoriasis patients’ attitudes toward benefit-
risk and therapeutic trade-offs in their choice of treatments. Patient Prefer.
Adherence 11, 353–362
112 Postmus, D. et al. (2018) Individual trade-offs between possible benefits and risks of
cancer treatments: results from a stated preference study with patients with
multiple myeloma. Oncologist 23, 44–51
113 Fraenkel, L. et al. (2017) Subjective numeracy and the influence of order and amount
of audible information on perceived medication value. Med. Decis. Mak. 37, 230–238
114 von Arx, L.B. et al. (2017) Be careful what you ask for: effects of benefit descriptions
on diabetes patients’ benefit-risk tradeoff preferences. Value Health 20, 670–678
115 Louviere, J.J. (2006) What you don’t know might hurt you: some unresolved issues in
the designand analysis ofdiscretechoice experiments. Environ. Res. Econ. 34,173–188
116 Fischhoff, B. et al. (2011) Communicating Risks and Benefits: An Evidence-Based User’s
Guide. FDA
117 EUPATI (2018) What is EUPATI? EUPATI value of patient preference studies along the medical product lifecycle: a literature review,
www.drugdiscoverytoday.com 11
REVIEWS Drug Discovery Today Volume 00, Number 00 October 2018
DRUDIS-2320; No of Pages 12
Review
s
FO
U
N
D
A
TIO
N
R
EV
IEW118 Anon (2005) Criteria for Judging the Quality of Patient Decision Aids. International
Patient Decision Aid Standards
119 Bowling, A. and Ebrahim, S. (2001) Measuring patients’ preferences for treatment
and perceptions of risk. Qual. Health Care 10 (Suppl. 1), i2–i8
120 Howard, K. and Salkeld, G. (2009) Does attribute framing in discrete choice
experiments influence willingness to pay? Results from a discrete choice
experiment in screening for colorectal cancer. Value Health 12, 354–363
121 Mu¨hlbacher, A. and Bethge, S. (2016) What matters in type 2 diabetes mellitus oral
treatment? A discrete choice experiment to evaluate patient preferences. Eur. J.
Health Econ. 17, 1125–2240
122 EMA (2014) Regulatory and Methodological Standards to Improve Benefit–Risk
Evaluation of Medicines. EMA
123 Hernandez Alava, M. et al. (2012) Tails from the peak district: adjusted limited
dependent variable mixture models of EQ-5D questionnaire health state utility
values. Value Health 15, 550–561Please cite this article in press as: van Overbeeke, E. et al. Factors and situations influencing the
Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.09.015
12 www.drugdiscoverytoday.com124 Brennan, D.F. (1995) Patient preferences. Ann. Emerg. Med. 26, 240–241
125 Brooker, A.S. et al. (2013) Quantitative patient preference evidence for health
technology assessment: a case study. Int. J. Technol. Assess. Health Care 29, 290–300
126 Ryan, M. et al. (2017) Using Discrete Choice Experiments in Health Economics:
Theoretical and Practical Issues. University of Aberdeen
127 ICH (2016) ICH Harmonised Guideline: Revision of M4E Guideline on Enhancing the
Format and Structure of Benefit-Risk Information in ICH. ICH
128 Brazier, J.E. et al. (2012) Developing and testing methods for deriving preference-
based measures of health from condition-specific measures (and other patient-
based measures of outcome). Health Technol. Assess. 16, 1–114
129 Danner, M. et al. (2011) Integrating patients’ views into health technology
assessment: analytic hierarchy process (AHP) as a method to elicit patient
preferences. Int. J. Technol. Assess. Health Care 27, 369–375 value of patient preference studies along the medical product lifecycle: a literature review,
